The most common familial mutation in LRRK2 (Gly2019Ser) has been demonstrated to increase LRRK2 kinase activity [23], leading to the development of small chemical kinase inhibitors as potential therapeutics for PD. This evidence concerns the gene LRRK2 and Parkinson disease.